<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "5: materially from", fill: "#f4a460"},
{source: "5: materially from", target: "5: the Stock Purchase ", fill: "#f4a460"},
{source: "5: the Stock Purchase ", target: "5: termination fee", fill: "#f4a460"},
{source: "5: termination fee", target: "5: common stock price", fill: "#f4a460"},
{source: "5: common stock price", target: "5: operations", fill: "#f4a460"},
{source: "5: materially from", target: "6: following risks", fill: "#78866b"},
{source: "6: following risks", target: "6: Stock Purchase ", fill: "#78866b"},
{source: "6: Stock Purchase ", target: "6: terminated under certain", fill: "#78866b"},
{source: "6: terminated under certain", target: "6: circumstances", fill: "#78866b"},
{source: "6: circumstances", target: "6: termination", fill: "#78866b"},
{source: "6: termination", target: "6: stock may decline", fill: "#78866b"},
{source: "6: stock may decline", target: "6: market price", fill: "#78866b"},
{source: "6: market price", target: "6: stock reflects", fill: "#78866b"},
{source: "6: stock reflects", target: "6: market assumption", fill: "#78866b"},
{source: "6: market assumption", target: "6: such as legal accounting", fill: "#78866b"},
{source: "6: such as legal accounting", target: "6: certain financial advisory fees must", fill: "#78866b"},
{source: "6: following risks", target: "7: Stock Purchase", fill: "#933d41"},
{source: "7: Stock Purchase", target: "7: directors", fill: "#933d41"},
{source: "7: directors", target: "7: combination there", fill: "#933d41"},
{source: "7: combination there", target: "7: partner willing", fill: "#933d41"},
{source: "7: partner willing", target: "7: attractive price than", fill: "#933d41"},
{source: "7: attractive price than", target: "7: paid by each party", fill: "#933d41"},
{source: "7: Stock Purchase", target: "9: general either party", fill: "#faf0be"},
{source: "9: general either party", target: "9: Stock Purchase ", fill: "#faf0be"},
{source: "9: Stock Purchase ", target: "9: affecting", fill: "#faf0be"},
{source: "9: affecting", target: "9: party between", fill: "#faf0be"},
{source: "9: party between", target: "9: December ", fill: "#faf0be"},
{source: "9: general either party", target: "10: certain types", fill: "#c19a6b"},
{source: "10: certain types", target: "10: Stock Purchase ", fill: "#c19a6b"},
{source: "10: Stock Purchase ", target: "10: from general economic conditions", fill: "#c19a6b"},
{source: "10: from general economic conditions", target: "10: conditions", fill: "#c19a6b"},
{source: "10: conditions", target: "10: generally affecting", fill: "#c19a6b"},
{source: "10: generally affecting", target: "10: respective company", fill: "#c19a6b"},
{source: "10: respective company", target: "10: either case", fill: "#c19a6b"},
{source: "10: either case", target: "10: materially", fill: "#c19a6b"},
{source: "10: materially", target: "10: situated businesses", fill: "#c19a6b"},
{source: "10: situated businesses", target: "10: announcement", fill: "#c19a6b"},
{source: "10: announcement", target: "10: completion", fill: "#c19a6b"},
{source: "10: completion", target: "10: transactions", fill: "#c19a6b"},
{source: "10: transactions", target: "10: accounting", fill: "#c19a6b"},
{source: "10: accounting", target: "10: requirements", fill: "#c19a6b"},
{source: "10: requirements", target: "10: regulations", fill: "#c19a6b"},
{source: "10: regulations", target: "10: interpretation thereof", fill: "#c19a6b"},
{source: "10: interpretation thereof", target: "10: trading volume", fill: "#c19a6b"},
{source: "10: trading volume", target: "10: applicable laws rules", fill: "#c19a6b"},
{source: "10: applicable laws rules", target: "10: common stock", fill: "#c19a6b"},
{source: "10: common stock", target: "10: preferred stock from", fill: "#c19a6b"},
{source: "10: certain types", target: "12: of the Stock Purchase ", fill: "#fc3"},
{source: "12: of the Stock Purchase ", target: "12: stockholders", fill: "#fc3"},
{source: "12: of the Stock Purchase ", target: "19: liquidation", fill: "#ffc40c"},
{source: "19: liquidation", target: "19: stock holders would likely", fill: "#ffc40c"},
{source: "19: stock holders would likely", target: "19: no distribution", fill: "#ffc40c"},
{source: "19: no distribution", target: "19: distribution", fill: "#ffc40c"},
{source: "19: distribution", target: "19: preferred stock", fill: "#ffc40c"},
{source: "19: preferred stock", target: "19: equity holders", fill: "#ffc40c"},
{source: "19: equity holders", target: "19: Xcytes ", fill: "#ffc40c"},
{source: "19: Xcytes ", target: "19: creditors", fill: "#ffc40c"},
{source: "19: creditors", target: "19: which amount", fill: "#ffc40c"},
{source: "19: which amount", target: "19: available cash would likely", fill: "#ffc40c"},
{source: "19: available cash would likely", target: "19: preference amount", fill: "#ffc40c"},
{source: "19: preference amount", target: "19: convertible preferred stock", fill: "#ffc40c"},
{source: "19: liquidation", target: "START_HERE", fill: "#ffc40c"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Employee_stock_purchase_plan">Employee stock purchase plan</a></td>
      <td>In the United States, an employee stock purchase plan (ESPP) is a means by which employees of a corporation can purchase the corporation's capital stock, often at a discount. Employees contribute to the plan through payroll deductions, which build up between the offering date and the purchase date.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Asset_purchase_agreement">Asset purchase agreement</a></td>
      <td>An asset purchase agreement (APA) is an agreement between a buyer and a seller that finalizes terms and conditions related to the purchase and sale of a company's assets. It's important to note in an APA transaction, it is not necessary for the buyer to purchase all of the assets of the company.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Employee_stock_ownership">Employee stock ownership</a></td>
      <td>Employee stock ownership, or employee share ownership, is where a company's employees own shares in that company (or in the parent company of a group of companies). US Employees typically acquire shares through a share option plan.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Benihana">Benihana</a></td>
      <td>Benihana Inc. (Japanese: 紅花, "Safflower") is an American restaurant company founded by Hiroaki Aoki in New York City in 1964 and currently based in Aventura, Florida.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Delta_Electric_Company">Delta Electric Company</a></td>
      <td>The Delta Electric Company was an American electronics manufacturer formed in 1913 in Marion, Indiana that produced lanterns, flashlights, automotive and bicycle lighting, battery tubes, horns, horn buttons, light switches, other battery-powered electrical parts, and bilge pumps. It was moved to Marion from an existing business in Chicago following a stock purchase.Delta was purchased in 1964 or 1965 by the Novo Industrial Corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_company">Public company</a></td>
      <td>A public company, publicly traded company, publicly held company, publicly listed company, or public limited company is a company whose ownership is organized via shares of stock which are intended to be freely traded on a stock exchange or in over-the-counter markets. A public (publicly traded) company can be listed on a stock exchange (listed company), which facilitates the trade of shares, or not (unlisted public company).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Equity_(finance)">Equity (finance)</a></td>
      <td>In finance, equity is ownership of assets that may have debts or other liabilities attached to them. Equity is measured for accounting purposes by subtracting liabilities from the value of the assets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Board_of_directors">Board of directors</a></td>
      <td>A board of directors (commonly referred simply as the board) is an executive committee that jointly supervises the activities of an organization, which can be either a for-profit or a nonprofit organization such as a business, nonprofit organization, or a government agency. \nThe powers, duties, and responsibilities of a board of directors are determined by government regulations (including the jurisdiction's corporate law) and the organization's own constitution and by-laws.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Daniels_(directors)">Daniels (directors)</a></td>
      <td>Daniel Kwan (Chinese: 關家永) and Daniel Scheinert, collectively known as Daniels or the Daniels, are a duo of film directors and writers. They began their career as directors of music videos, including the popular DJ Snake promotional for the single "Turn Down for What" (2013).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Directors'_Fortnight">Directors' Fortnight</a></td>
      <td>The Directors' Fortnight (French: Quinzaine des Réalisateurs) is an independent selection of the Cannes Film Festival. It was started in 1969 by the French Directors Guild after the events of May 1968 resulted in cancellation of the Cannes festival as an act of solidarity with striking workers.The Directors' Fortnight showcases a programme of shorts and feature films and documentaries worldwide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chief_executive_officer">Chief executive officer</a></td>
      <td>A chief executive officer (CEO), chief administrator officer (CAO), central executive officer (CEO), or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization –  especially an independent legal entity such as a company or nonprofit institution. CEOs find roles in a range of organizations, including public and private corporations, non-profit organizations and even some government organizations (notably state-owned enterprises).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Executive_director">Executive director</a></td>
      <td>An executive director is a member of a board of directors for an organisation, but the meaning of the term varies between countries.\n\n\n== United States ==\nIn the US, an executive director is a chief executive officer (CEO) or managing director of an organization, company, or corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nelson_(director)">Nelson (director)</a></td>
      <td>Nelson Dilipkumar, credited in films as Nelson, is an Indian director and screenwriter who predominantly works in Tamil cinema. His films are known for featuring elements of Dark Humour.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bala_(director)">Bala (director)</a></td>
      <td>Balasubramanian known as Bala is an Indian film director, screenwriter, and producer, working in Tamil cinema. Often considered to be one of the finest directors in Tamil, Bala is widely acclaimed for "revolutionizing Tamil cinema" through his realistic, dark and disturbing depiction of the working class on celluloid screen.Just within directing a handful of films, his movies went on to win 6 National Awards, 13 State awards, 15 Filmfare Awards, 14 International Festival Awards and numerous coveted state awards which created a storm within the Indian movie scene.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December">December</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots. Italy still prohibits offensive strikes, and reserves the right to veto U.S. missions.2 JanuaryIndian aerial surveillance detected gunmen entering an Indian Air Force base at Pathankot, and their security forces exchange fire with them in a housing area.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Participating_preferred_stock">Participating preferred stock</a></td>
      <td>Participating preferred stock is preferred stock that provides a specific dividend that is paid before any dividends are paid to common stock holders, and that takes precedence over common stock in the event of a liquidation. This form of financing is used by private equity investors and venture capital (VC) firms.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholder">Shareholder</a></td>
      <td>A shareholder (in the United States often referred to as stockholder) of a corporation is an individual or legal entity (such as another corporation, a body politic, a trust or partnership) that is registered by the corporation as the legal owner of shares of the share capital of a public or private corporation. Shareholders may be referred to as members of a corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stockholder_of_record">Stockholder of record</a></td>
      <td>Stockholder of record is the name of an individual or entity shareholder that an issuer carries in its shareholder register as the registered holder (not necessarily the beneficial owner) of the issuer's securities. Dividends and other distributions are paid only to shareholders of record.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Jessica_Stockholder">Jessica Stockholder</a></td>
      <td>Jessica Stockholder (born 1959) is a Canadian-American artist known for site-specific installation works and sculptures that are often described as "paintings in space." She came to prominence in the early 1990s with monumental works that challenged boundaries between artwork and display environment as well as between pictorial and physical experience. Her art often presents a "barrage" of bold colors, textures and everyday objects, incorporating floors, walls and ceilings and sometimes spilling out of exhibition sites.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Derivative_suit">Derivative suit</a></td>
      <td>A shareholder derivative suit is a lawsuit brought by a shareholder on behalf of a corporation against a third party. Often, the third party is an insider of the corporation, such as an executive officer or director.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Friedman_doctrine">Friedman doctrine</a></td>
      <td>The Friedman doctrine, also called shareholder theory or stockholder theory, is a normative theory of business ethics advanced by economist Milton Friedman which holds that the social responsibility of business is to increase its profits. This shareholder primacy approach views shareholders as the economic engine of the organization and the only group to which the firm is socially responsible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_security">Convertible security</a></td>
      <td>A convertible security is a financial instrument whose holder has the right to convert it into another security of the same issuer. Most convertible securities are convertible bonds or preferred stocks that pay regular interest and can be converted into shares of the issuer's common stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Death_spiral_financing">Death spiral financing</a></td>
      <td>Death spiral financing is the result of a badly structured convertible financing used to fund primarily small cap companies in the marketplace, causing the company's stock to fall dramatically, which can lead to the company's ultimate downfall. \nSome small companies rely on selling convertible debt to large private investors (see private investment in public equity) to fund their operations and growth.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>XCYTE THERAPIES INC      ITEM 1A RISK FACTORS        Important Factors That May Affect Our Business, Results of Operations and     Stock Price        You <font color="blue">should carefully</font> consider the <font color="blue">risks described</font> below, <font color="blue">together with</font> all     of the other information included in this annual report on Form 10-K and the     information <font color="blue"><font color="blue">incorporated</font> by reference herein</font></td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">effectively</font>     address the risks we face, our business will suffer and we may never achieve     or <font color="blue">sustain <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>See “Management’s Discussion and Analysis of     <font color="blue">Financial Condition and Results of Operations</font></td>
    </tr>
    <tr>
      <td>”       This annual report on Form 10-K also contains forward-looking statements     that  <font color="blue">involve risks</font> and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>Our actual results could differ     <font color="blue"><font color="blue">materially</font> from</font> those anticipated in the forward-looking statements as a     result of factors that are described below and elsewhere in this annual     report on Form 10-K       RISK FACTORS        Risks Related to <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>       Failure  to  complete  <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>may result in Xcyte paying a     <font color="blue"><font color="blue">termination</font> fee</font> to Cyclacel and could harm Xcyte’s <font color="blue"><font color="blue">common stock</font> price</font> and     future business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If  the  Stock  Purchase is not completed, Xcyte may be subject to the     <font color="blue">following risks</font>:           •   if <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>Agreement is <font color="blue">terminated under certain</font>     <font color="blue">circumstances</font>, Xcyte will be required to pay the other party a <font color="blue">termination</font>     fee of dlra100cmam000;           •   the price of Xcyte <font color="blue">stock may decline</font> to the extent that the current     <font color="blue">market price</font> of Xcyte <font color="blue">stock reflects</font> a <font color="blue">market assumption</font> that the Stock     Purchase will be completed; and           •   costs related to the <font color="blue">Stock Purchase</font>, such as legal, <font color="blue">accounting</font> and     certain financial advisory fees, must be paid even if <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>is     not completed</td>
    </tr>
    <tr>
      <td>In addition, if <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>Agreement is terminated and Xcyte’s board     of <font color="blue">directors</font> determines to seek another business <font color="blue">combination</font>, there can be     no  assurance that it will be able to find a <font color="blue">partner willing</font> to pay an     equivalent or more <font color="blue">attractive price than</font> the price to be <font color="blue">paid by each party</font>     in the <font color="blue">Stock Purchase</font></td>
    </tr>
    <tr>
      <td>7     ______________________________________________________________________    [33]Table of <font color="blue">Contents       </font>The <font color="blue"><font color="blue">Stock Purchase</font> </font>may be completed <font color="blue">even though</font> material adverse changes may     result from the <font color="blue">announcement</font> of the <font color="blue">Stock Purchase</font>, industry-wide changes     and other causes</td>
    </tr>
    <tr>
      <td>In general, either party can refuse to complete <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>if there     is a material adverse change <font color="blue">affecting</font> the other <font color="blue">party between</font> the date of     signing (<font color="blue">December </font>15, 2005) and the closing</td>
    </tr>
    <tr>
      <td>However, <font color="blue">certain types</font> of     changes will not prevent <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>from being completed, even if     they would have a material adverse effect on Xcyte, including:           •   changes resulting <font color="blue">from general economic <font color="blue">conditions</font></font> or <font color="blue">conditions</font>     generally <font color="blue">affecting</font> the industry in which the <font color="blue">respective company</font> operates,     except in <font color="blue">either case</font> to the extent the <font color="blue">respective company</font> is <font color="blue">materially</font>     disproportionately <font color="blue">adversely</font> affected thereby relative to other similarly     <font color="blue">situated businesses</font>;           •   changes due to the <font color="blue">announcement</font> of the execution of <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>    Agreement or the <font color="blue">completion</font> of the <font color="blue"><font color="blue">transaction</font>s</font> contemplated by the Stock     Purchase Agreement;           •   changes resulting from or relating to any change in <font color="blue">accounting</font>     <font color="blue"><font color="blue">requirement</font>s</font> or principles or any change in applicable laws, rules or     <font color="blue">regulations</font> or the <font color="blue">interpretation thereof</font>;           •   changes resulting from a change in the stock price or <font color="blue">trading volume</font>     of Xcyte excluding any underlying effect that may have caused such change;     or           •   changes resulting from the delisting or threatened or potential     delisting of Xcyte <font color="blue">common stock</font> or <font color="blue"><font color="blue">preferred stock</font> from</font> the Nasdaq Stock     Market</td>
    </tr>
    <tr>
      <td>If adverse changes occur but Xcyte must still complete the <font color="blue">Stock Purchase</font>,     Xcyte’s <font color="blue"><font color="blue">stock price may</font> suffer</font></td>
    </tr>
    <tr>
      <td>This in turn may reduce the value of the     <font color="blue"><font color="blue">Stock Purchase</font> </font>to the <font color="blue">stockholders</font> of Xcyte</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of Xcyte common <font color="blue">stock may decline</font> as a result of the Stock     Purchase for a number of reasons including if:           •   Xcyte does not achieve the perceived benefits of <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>as     rapidly or to the extent anticipated by financial or <font color="blue">industry analysts</font>;           •   the effect of <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>on Xcyte’s business and prospects is     not <font color="blue">consistent with</font> the <font color="blue">expectations</font> of financial or <font color="blue">industry analysts</font>; or           •   <font color="blue">investors react negatively</font> to the effect on Xcyte’s business and     <font color="blue">prospects from</font> the <font color="blue">Stock Purchase</font></td>
    </tr>
    <tr>
      <td>Xcyte  <font color="blue">stockholders</font>  may not realize a <font color="blue">benefit from</font> <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>    <font color="blue">commensurate with</font> the <font color="blue">ownership dilution</font> they will experience in <font color="blue">connection</font>     with the <font color="blue">Stock Purchase</font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">combined company</font> is unable to realize the strategic and financial     benefits currently anticipated from the <font color="blue">Stock Purchase</font>, Xcyte will have     experienced  substantial  dilution of their <font color="blue">ownership interest without</font>     receiving any <font color="blue">commensurate benefit</font></td>
    </tr>
    <tr>
      <td>Failure to complete <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>may result in the <font color="blue">liquidation</font> of the     Company and the <font color="blue">common stock</font> may have no value</td>
    </tr>
    <tr>
      <td>If <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>is not completed, it may be <font color="blue">difficult</font> to <font color="blue">enter into</font>     another business <font color="blue">combination</font>, for <font color="blue">several reasons</font>, including (i) Xcyte will     have a <font color="blue">reduced cash position over</font> time; (ii) it is likely that Xcyte’s     common  stock  will  be  <font color="blue">delisted from</font> the NASDAQ National Market; and     (iii) Xcyte  may  not have the <font color="blue"><font color="blue">management</font> personnel</font> to execute another     <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>If  <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>is not completed and Xcyte cannot     <font color="blue">expeditiously</font> achieve another business <font color="blue">combination</font> <font color="blue">transaction</font>, then <font color="blue">Xcyte     </font><font color="blue">would likely</font> be liquidated</td>
    </tr>
    <tr>
      <td>If <font color="blue">liquidation</font> were to occur, Xcyte’s common     stock holders <font color="blue">would likely</font> receive little or <font color="blue">no <font color="blue">distribution</font></font> because the     holders  of <font color="blue">preferred stock</font> of Xcyte would have preference to the cash     available  for <font color="blue">distribution</font> to <font color="blue">equity holders</font> after payment of Xcyte’s     <font color="blue">creditors</font>,  <font color="blue">which amount</font> of available cash <font color="blue">would likely</font> not exceed the     <font color="blue">preference amount</font> of Xcyte’s convertible <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>Risks related to Xcyte’s Business</td>
    </tr>
    <tr>
      <td>The <font color="blue">attempted development</font> of <font color="blue">products using</font> Xcyte’s <font color="blue">Xcellerate Technology </font>    was Xcyte’s <font color="blue">only potential <font color="blue">product line</font></font></td>
    </tr>
    <tr>
      <td>Xcyte has not <font color="blue">successfully</font> developed any <font color="blue"><font color="blue">product line</font> with</font> its Xcellerate     Technology</td>
    </tr>
    <tr>
      <td>Xcyte plans to sell all rights to its <font color="blue">Xcellerate Technology </font>and     all related assets <font color="blue">to Invitrogen </font>in <font color="blue">connection</font> with the Asset Purchase     Agreement described above</td>
    </tr>
    <tr>
      <td>Following <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>Xcyte plans to     conduct the business that is now being <font color="blue">conducted by</font> Cyclacel</td>
    </tr>
    <tr>
      <td>Xcyte has no     plans  to  pursue  any  other  <font color="blue">product line</font> other <font color="blue">than pursuant</font> to the     <font color="blue">acquisition</font> of Cyclacel pursuant to the <font color="blue">Stock Purchase</font></td>
    </tr>
    <tr>
      <td>Xcyte may not be able to retain <font color="blue">existing personnel</font></td>
    </tr>
    <tr>
      <td>Xcyte’s <font color="blue">remaining staff</font>,     as of January 23, 2006 consisted of <font color="blue">five employees</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">uncertainty</font> of the     outcome of Xcyte’s review of <font color="blue"><font color="blue">strategic alternative</font>s</font>, workforce reductions     and the <font color="blue">volatility</font> in its <font color="blue">stock price may</font> create anxiety and <font color="blue">uncertainty</font>,     <font color="blue">which may <font color="blue">adversely</font> affect employee morale</font> and cause Xcyte to lose employees     whom it would prefer to retain</td>
    </tr>
    <tr>
      <td>To the extent that Xcyte is unable to retain     its  existing  personnel, its business and ability to <font color="blue">pursue strategic</font>     <font color="blue">alternatives may suffer</font></td>
    </tr>
    <tr>
      <td>In addition, this <font color="blue">workforce reduction may</font> subject     Xcyte to the risk of <font color="blue">litigation</font>, <font color="blue">which could</font> result in substantial costs and     could divert <font color="blue">management</font>’s time and <font color="blue">attention away from</font> business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Xcyte expects to continue to incur substantial losses and may never achieve     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Xcyte has incurred <font color="blue">significant</font> operating <font color="blue">losses since</font> it began <font color="blue">operations</font> in     1996, including net losses of <font color="blue">approximately</font> dlra29dtta4 million for the year ended     <font color="blue">December </font>31, 2005 and Xcyte <font color="blue">may never become profitable</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31,     2005, Xcyte had an <font color="blue">accumulated deficit since inception</font> of <font color="blue">approximately</font>     dlra155dtta6 million</td>
    </tr>
    <tr>
      <td>These losses have resulted <font color="blue">principally from costs incurred</font>     in  Xcyte’s research and <font color="blue">development programs</font> and from its general and     <font color="blue">administrative expenses</font></td>
    </tr>
    <tr>
      <td>To date, Xcyte has <font color="blue">derived no revenues from product</font>     sales or royalties</td>
    </tr>
    <tr>
      <td>Xcyte does not expect to have any <font color="blue">product sales</font> or     <font color="blue">royalty revenue</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Xcyte’s operating losses have     <font color="blue">been increasing during</font> the <font color="blue">past several years</font> and <font color="blue">may increase <font color="blue">significant</font>ly</font>     in the future</td>
    </tr>
    <tr>
      <td>Xcyte also may be required to recognize <font color="blue"><font color="blue">additional</font> losses</font>     <font color="blue">based upon</font> changes in the <font color="blue">fair value</font> of its derivative <font color="blue">liability</font>, which     resulted from the dividend make-whole payment feature of its convertible     preferred  stock</td>
    </tr>
    <tr>
      <td>These losses, among other things, have had and will     continue to have an adverse effect on Xcyte’s <font color="blue">stockholders</font>’ equity and     working capital</td>
    </tr>
    <tr>
      <td>Xcyte is unable to predict when it <font color="blue">may become profitable</font>,     if at all</td>
    </tr>
    <tr>
      <td>If Xcyte is unable to achieve and then maintain <font color="blue">profitability</font>,     the <font color="blue">market value</font> of its <font color="blue">common stock</font> and convertible <font color="blue">preferred stock</font> will     <font color="blue">likely decline</font></td>
    </tr>
    <tr>
      <td>8     ______________________________________________________________________    [34]Table of <font color="blue">Contents       </font>Xcyte may be unable to maintain its <font color="blue">listing on</font> Nasdaq, <font color="blue">which could</font> cause     Xcyte’s stock price to fall and decrease the liquidity of its stock</td>
    </tr>
    <tr>
      <td>Xcyte <font color="blue">common stock</font> and convertible <font color="blue">preferred stock</font> are <font color="blue">currently traded on</font>     the <font color="blue">Nasdaq National Market</font>, which has compliance <font color="blue"><font color="blue">requirement</font>s</font> for continued     listing, including a <font color="blue">requirement</font> that Xcyte <font color="blue">common stock</font> and convertible     <font color="blue">preferred stock</font> each have a <font color="blue">minimum bid price</font> of dlra1dtta00 per share</td>
    </tr>
    <tr>
      <td>On June 6,     2005, Xcyte received a notice from the <font color="blue">Nasdaq Stock Market </font>that for 30     <font color="blue">consecutive trading days</font> the bid price of its <font color="blue">common stock</font> had closed below     the minimum dlra1dtta00 per share <font color="blue">requirement</font> and, as a result, its <font color="blue">common stock</font>     <font color="blue">no longer complied with</font> Nasdaq ’<font color="blue">s continued listing criteria</font></td>
    </tr>
    <tr>
      <td>The letter     stated  that  Xcyte would be provided with 180 calendar days, or until     <font color="blue">December </font>5, 2005, to <font color="blue">regain compliance</font></td>
    </tr>
    <tr>
      <td>Xcyte <font color="blue">common stock</font> did not regain     <font color="blue">compliance with</font> this <font color="blue">requirement</font> by <font color="blue">December </font>5, 2005, and Xcyte received a     notice on <font color="blue">December </font>5, 2005 from the <font color="blue">Nasdaq Stock Market </font>that its common     <font color="blue">stock would</font> be delisted</td>
    </tr>
    <tr>
      <td>Xcyte appealed Nasdaq’s de<font color="blue">termination</font> and appeared     before  a  <font color="blue">Nasdaq Listing Qualifications Panel </font>on January 12, 2006</td>
    </tr>
    <tr>
      <td>On     February  7,  2006,  the <font color="blue">Nasdaq Listing Qualifications Panel </font>granted a     <font color="blue">continuation</font> of Xcyte’s <font color="blue">listing on</font> the <font color="blue"><font color="blue">Nasdaq National Market</font> </font>subject to     certain <font color="blue">conditions</font>, including the <font color="blue">consummation</font> of <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>and     Nasdaq’s approval of an <font color="blue">initial listing <font color="blue">application</font></font> for the shares of the     <font color="blue"><font color="blue">combined company</font> pursuant</font> to Nasdaq’s “reverse merger” rules on or before     April 12, 2006 (discussed below)</td>
    </tr>
    <tr>
      <td>On  <font color="blue">December </font> 28,  2005, the <font color="blue">Nasdaq Stock Market </font>advised Xcyte that it     considers  the  <font color="blue"><font color="blue">Stock Purchase</font> </font>to be a “reverse merger” under Nasdaq’s     Marketplace Rules</td>
    </tr>
    <tr>
      <td>Based on this <font color="blue">conclusion</font>, Nasdaq advised Xcyte that upon     <font color="blue">consummation</font> of the <font color="blue">Stock Purchase</font>, Xcyte’s <font color="blue">common stock</font> and convertible     <font color="blue">preferred stock</font> will not be permitted to continue to trade on the Nasdaq     National Market unless a new <font color="blue">initial listing <font color="blue">application</font></font> for the stock of     the <font color="blue">combined company</font> is filed and approved before <font color="blue">consummation</font> of the Stock     Purchase</td>
    </tr>
    <tr>
      <td>Cyclacel Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>(as Xcyte will be <font color="blue">renamed following</font>     the <font color="blue">Stock Purchase</font>) has filed an <font color="blue">initial listing <font color="blue">application</font></font> for the listing     of Xcyte’s <font color="blue">common stock</font> and convertible <font color="blue">preferred stock</font> following the Stock     Purchase on the <font color="blue"><font color="blue">Nasdaq National Market</font> </font>under the <font color="blue">trading symbols</font> “CYCC” and     “CYCCP”, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">initial listing <font color="blue">application</font></font> has not yet been     <font color="blue">approved as</font> to either class of stock and the <font color="blue">application</font> is subject to     <font color="blue">separate consideration <font color="blue">with respect</font></font> to each class of Xcyte stock</td>
    </tr>
    <tr>
      <td>In order     for such <font color="blue">application</font> to be <font color="blue">approved <font color="blue">with respect</font></font> to either the <font color="blue">common stock</font>     or the convertible <font color="blue">preferred stock</font>, such class must meet all of the initial     inclusion  criteria for initial <font color="blue">listing on</font> the <font color="blue">Nasdaq National Market</font>,     including a minimum closing bid price of dlra5dtta00 per share</td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>22,     2006, the bid price for both Xcyte’s <font color="blue">common stock</font> and Xcyte’s convertible     <font color="blue">preferred stock</font> were below the <font color="blue">minimum bid price</font> of dlra5dtta00 per share</td>
    </tr>
    <tr>
      <td>While     Xcyte is hopeful that following the anticipated one for ten <font color="blue">common stock</font>     <font color="blue">reverse stock split approved by</font> Xcyte’s <font color="blue">stockholders</font> on March 16, 2006, the     bid price for Xcyte’s <font color="blue">common stock</font> may rise above the dlra5dtta00 minimum bid     price per share, Xcyte <font color="blue">cannot give</font> any assurance that this will occur</td>
    </tr>
    <tr>
      <td>Moreover, Xcyte cannot anticipate whether or not the <font color="blue">minimum bid price</font> for     Xcyte’s convertible <font color="blue">preferred stock</font> will rise above dlra5dtta00 per share prior to     the closing of the <font color="blue">Stock Purchase</font></td>
    </tr>
    <tr>
      <td>If  the Nasdaq does not approve the listing of Xcyte’s <font color="blue">common stock</font> or     convertible  <font color="blue">preferred stock</font> for <font color="blue">trading on</font> the <font color="blue"><font color="blue">Nasdaq National Market</font> </font>    following the <font color="blue">Stock Purchase</font>, upon closing of <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>the class     (or classes) of Xcyte’s stock for which such <font color="blue">application</font> is not approved     <font color="blue">will no longer</font> be listed for <font color="blue">trading on</font> the <font color="blue">Nasdaq National Market</font></td>
    </tr>
    <tr>
      <td>In such     case,  Xcyte may seek to have the <font color="blue">applicable shares</font> of <font color="blue">common stock</font> or     convertible <font color="blue">preferred stock</font> listed for <font color="blue">trading on</font> the <font color="blue">Nasdaq Capital Market</font></td>
    </tr>
    <tr>
      <td>Xcyte <font color="blue">cannot assure</font> you that it would be able to obtain listing for its     shares of <font color="blue">common stock</font> or <font color="blue"><font color="blue">convertible preferred</font> following</font> <font color="blue">the <font color="blue"><font color="blue">Stock Purchase</font> </font></font>    on the <font color="blue"><font color="blue">Nasdaq National Market</font> </font>or the <font color="blue">Nasdaq Capital Market</font> or that it will     be able on an ongoing basis to meet the maintenance <font color="blue"><font color="blue">requirement</font>s</font> thereof</td>
    </tr>
    <tr>
      <td>If Xcyte’s shares of stock were to be <font color="blue">delisted from</font> <font color="blue">trading on</font> the Nasdaq     National Market and were neither relisted thereon nor listed for <font color="blue">trading on</font>     the <font color="blue">Nasdaq Capital Market</font>, trading, if any, in Xcyte’s <font color="blue">stock may continue</font> to     be <font color="blue">conducted on</font> the <font color="blue">OTC Bulletin Board </font>or in a non-Nasdaq over-the-counter     market, such as the “<font color="blue">pink sheets</font></td>
    </tr>
    <tr>
      <td>” Delisting of Xcyte’s shares of common     <font color="blue">stock would</font> result in limited release of the <font color="blue">market price</font> of those shares of     <font color="blue">common stock</font> and limited <font color="blue">analyst coverage</font> and <font color="blue">could restrict investors</font>’     interest in Xcyte’s securities</td>
    </tr>
    <tr>
      <td>Also, a delisting could <font color="blue">materially</font> <font color="blue">adversely</font>     affect the trading market and prices for Xcyte’s stock and its ability to     <font color="blue">issue <font color="blue">additional</font> securities</font> or to <font color="blue">secure <font color="blue">additional</font> financing</font></td>
    </tr>
    <tr>
      <td>In addition,     if Xcyte’s stock were not listed and the <font color="blue">trading price</font> of its shares of     <font color="blue">common stock</font> was less than dlra5 per share, Xcyte’s shares of <font color="blue">common stock</font>     could be subject to Rule 15g-9 under the <font color="blue">Securities Exchange Act </font>of 1934     which, among other things, requires that broker/dealers satisfy special     sales  practice  <font color="blue"><font color="blue">requirement</font>s</font>, including making <font color="blue">individualized</font> written     <font color="blue">suitability</font> de<font color="blue">termination</font>s and receiving a purchaser’s written consent prior     to any <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>In such case, Xcyte’s <font color="blue">securities could also</font> be deemed to     be a “<font color="blue">penny stock</font>” under the Securities Enforcement and Penny Stock Reform     Act of 1990, which would require <font color="blue">additional</font> <font color="blue">disclosure</font> in <font color="blue">connection</font> with     trades  in  those  shares of <font color="blue">common stock</font>, including the delivery of a     <font color="blue">disclosure</font> schedule explaining the nature and risks of the <font color="blue">penny stock</font>     market</td>
    </tr>
    <tr>
      <td>Such <font color="blue"><font color="blue">requirement</font>s</font> could severely limit the liquidity of Xcyte’s     securities</td>
    </tr>
    <tr>
      <td>Xcyte may have limited ability to <font color="blue">pay cash dividends on</font> the convertible     <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Delaware </font> </font>law  may  limit Xcyte’s ability to <font color="blue">pay cash dividends on</font> the     convertible <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Under <font color="blue">Delaware </font></font>law, cash dividends on Xcyte’s     capital  stock  may  only  be  paid  from “surplus” or, if there is no     “surplus,” from the <font color="blue">corporation</font>’s net profits for the current or preceding     <font color="blue">fiscal year</font></td>
    </tr>
    <tr>
      <td><font color="blue">Delaware </font>law defines “surplus” as the <font color="blue">amount by which</font> the total     assets of a <font color="blue">corporation</font>, after subtracting its total <font color="blue">liabilities</font>, exceed the     <font color="blue">corporation</font>’s capital, as determined by its board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Since <font color="blue">Xcyte     </font>is  not profitable, its ability to <font color="blue">pay cash dividends will</font> require the     <font color="blue">availability</font> of <font color="blue">adequate surplus</font></td>
    </tr>
    <tr>
      <td>Even if <font color="blue">adequate surplus</font> is available to     <font color="blue">pay cash dividends on</font> the convertible <font color="blue">preferred stock</font>, Xcyte may not have     <font color="blue">sufficient cash</font> to <font color="blue">pay dividends on</font> the convertible <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>If that     was  to  happen,  holders  of <font color="blue">preferred stock</font> would be <font color="blue">granted certain</font>     <font color="blue">additional</font> rights until such dividends were repaid</td>
    </tr>
    <tr>
      <td>There  are <font color="blue">risks inherent</font> in Xcyte’s past business <font color="blue">operations</font> that may     subject it to <font color="blue">potential product <font color="blue">liability</font> suits</font> and other claims, which may     require it to engage in expensive and time-consuming <font color="blue">litigation</font> or pay     substantial damages</td>
    </tr>
    <tr>
      <td>Xcyte’s past business <font color="blue">operations</font> expose it to product <font color="blue">liability</font> risks, which     are  inherent  in  the  testing,  manufacturing, marketing and sale of     <font color="blue">biopharmaceutical products</font> and these <font color="blue">risks will continue</font> to effect <font color="blue">Xcyte     </font>after  the <font color="blue">Stock Purchase</font></td>
    </tr>
    <tr>
      <td>Even if Xcyte does not decide to resume the     <font color="blue">clinical development</font> of its products, Xcyte faces a risk of <font color="blue">clinical trial</font>     <font color="blue">liability</font> claims in the event that the prior use, or misuse, of its product     candidates during <font color="blue">clinical trial</font>s resulted in <font color="blue">personal injury</font> or death</td>
    </tr>
    <tr>
      <td>An     individual may bring a product <font color="blue">liability</font> claim against Xcyte if Xcellerated     T Cells cause, or merely appear to have caused, an injury</td>
    </tr>
    <tr>
      <td>Xcyte currently has <font color="blue">clinical trial</font> insurance that covers its <font color="blue">clinical trial</font>s     up to dlra5dtta0 million per occurrence with a dlra5dtta0 million aggregate limit</td>
    </tr>
    <tr>
      <td>However, due to <font color="blue">factors outside</font> of Xcyte’s control, including the risks     discussed above as well as <font color="blue">conditions</font> in the <font color="blue">relevant insurance markets</font>,     Xcyte may not be able to <font color="blue">renew such coverage on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>Furthermore, even if Xcyte <font color="blue">secures coverage</font>, it may not be able to obtain     policy  limits  adequate to satisfy any <font color="blue">liability</font> that may arise</td>
    </tr>
    <tr>
      <td>If a     successful product <font color="blue">liability</font> or other claim or series of claims is brought     against Xcyte for un<font color="blue">insured <font color="blue">liabilities</font></font> or in excess of <font color="blue">insured <font color="blue">liabilities</font></font>,     its <font color="blue">assets may</font> not be sufficient to cover these claims and its business     <font color="blue">operations</font> could suffer</td>
    </tr>
    <tr>
      <td>If Xcyte’s principal <font color="blue">stockholders</font>, executive officers and <font color="blue">directors</font> choose     to act together, they may be able to control its <font color="blue">management</font> and <font color="blue">operations</font>,     acting  in  their  best  interests  and not <font color="blue">necessarily</font> those of other     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Xcyte’s  executive officers, <font color="blue">directors</font> and principal <font color="blue">stockholders</font>, and     entities affiliated with them, beneficially own a <font color="blue"><font color="blue">significant</font> percentage</font> of     its  common  stock  and  convertible <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">significant</font>     <font color="blue">concentration</font> of share ownership may <font color="blue">adversely</font> affect the <font color="blue">trading price</font> of     Xcyte <font color="blue">common stock</font> because <font color="blue">investors often</font> perceive <font color="blue">disadvantages</font> in owning     stock in companies with controlling <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">stockholders</font>, acting     together, have the ability to exert substantial <font color="blue">influence over</font> all matters     requiring <font color="blue">approval by</font> Xcyte’s <font color="blue">stockholders</font>, including the election and     removal of <font color="blue">directors</font> and any proposed <font color="blue">Stock Purchase</font>, <font color="blue">consolidation</font> or sale     of all or <font color="blue">substantially</font> all of Xcyte’s assets</td>
    </tr>
    <tr>
      <td>In addition, they could     dictate the <font color="blue">management</font> of Xcyte’s business and affairs</td>
    </tr>
    <tr>
      <td>This <font color="blue">concentration</font>     of <font color="blue">ownership could</font> have the effect of delaying, deferring or preventing a     change in control of Xcyte or impeding a stock purchase, <font color="blue">consolidation</font>,     takeover or other business <font color="blue">combination</font> that could be favorable to you</td>
    </tr>
    <tr>
      <td>Since     Xcyte  convertible  <font color="blue">preferred stock</font> has limited <font color="blue">voting rights prior</font> to     <font color="blue">conversion</font>, holders of its convertible <font color="blue">preferred stock</font> will have little or     no  ability to control the outcome of a stockholder vote, except under     certain <font color="blue">circumstances</font> where a class vote of Xcyte <font color="blue">convertible preferred</font>     stock will be required,                                           9     ______________________________________________________________________    [35]Table of <font color="blue">Contents       </font>including,  among  others,  upon  certain  <font color="blue">amendments</font> to the Company’s     <font color="blue">certificate</font> of in<font color="blue">corporation</font> or bylaws or upon a share exchange, stock     purchase  or  <font color="blue">consolidation</font>  of  the  Company unless Xcyte’s shares of     convertible  <font color="blue">preferred stock</font> remain outstanding and <font color="blue">unaffected by such</font>     <font color="blue">transaction</font> or <font color="blue">convert into</font> similar <font color="blue">preferred stock</font> of the surviving entity     pursuant to such <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>Xcyte will soon be required to <font color="blue">comply with</font> Section 404 of the Sarbanes-Oxley     Act of 2002 regarding internal control <font color="blue">attestation</font> and any <font color="blue">inability</font> to do     so <font color="blue">may negatively impact</font> the report on its <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>Section 404 of the Sarbanes-Oxley Act of 2002 requires Xcyte’s <font color="blue">management</font> to     assess the <font color="blue">effectiveness</font> of its <font color="blue">internal controls</font> over financial reporting     and include an assertion in Xcyte’s annual report as to the <font color="blue">effectiveness</font> of     its <font color="blue">controls beginning</font> the year ending <font color="blue">December </font>31, 2007, assuming <font color="blue">Xcyte     </font>remains  a  non-accelerated  filer  as  defined  per  SEC <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Subsequently, Xcyte’s independent registered public <font color="blue">accounting</font> firm will be     required to attest to whether Xcyte’s <font color="blue">assessment</font> of the <font color="blue">effectiveness</font> of its     <font color="blue">internal control over financial</font> reporting is fairly stated in all material     respects and <font color="blue">separately</font> report on whether it believes Xcyte maintained, in     all material respects, effective <font color="blue">internal control over financial</font> reporting     for  the year ending <font color="blue">December </font>31, 2007</td>
    </tr>
    <tr>
      <td>Due to the <font color="blue">recent departure</font> of     Xcyte’s Associate Director of SEC Reporting and its Controller, as well as     any <font color="blue">difficult</font>ies Xcyte may have in retaining its <font color="blue">current personnel</font> and the     transition to <font color="blue">new employees following</font> the <font color="blue">Stock Purchase</font>, Xcyte cannot     assure you that it will be able to identify <font color="blue">deficiencies</font> in its internal     controls, remediate such <font color="blue">deficiencies</font> in a <font color="blue">timely manner</font> or <font color="blue">comply with</font> the     Section 404 <font color="blue">disclosure</font> <font color="blue"><font color="blue">requirement</font>s</font> for the year ending <font color="blue">December </font>31, 2007</td>
    </tr>
    <tr>
      <td>If Xcyte identifies <font color="blue">deficiencies</font> in its <font color="blue">existing <font color="blue">internal controls</font></font> and are     not able to remediate such <font color="blue">deficiencies</font> in a <font color="blue">timely fashion</font> or otherwise     <font color="blue">comply with</font> the Section 404 <font color="blue">disclosure</font> <font color="blue"><font color="blue">requirement</font>s</font> for the year ending     <font color="blue">December </font>31, 2007, Xcyte will not be able to <font color="blue">give assurance</font> regarding the     <font color="blue">effectiveness</font> of its <font color="blue">internal controls</font> and the report on its financial     <font color="blue">statements provided by</font> its <font color="blue">independent auditors may</font> be <font color="blue">negatively impacted</font></td>
    </tr>
    <tr>
      <td>Xcyte’s common and convertible <font color="blue">preferred stock</font> may experience <font color="blue">extreme price</font>     and volume <font color="blue">fluctuation</font>s, <font color="blue">which could</font> lead to <font color="blue">costly <font color="blue">litigation</font></font> for Xcyte and     make an <font color="blue">investment</font> in Xcyte <font color="blue">less appealing</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of Xcyte’s common and convertible <font color="blue">preferred stock</font> may     fluctuate <font color="blue">substantially</font> due to a variety of factors, including:           •   the course of action that Xcyte takes <font color="blue">with respect</font> to the review of     its <font color="blue"><font color="blue">strategic alternative</font>s</font>;           •   <font color="blue">additions</font> to or <font color="blue">departures</font> of Xcyte’s <font color="blue">key personnel</font>;           •   <font color="blue">announcement</font>s of <font color="blue">technological innovations</font> or <font color="blue">new products</font> or services     by Xcyte or its <font color="blue">competitors</font>;           •   media reports and <font color="blue">publications</font> about <font color="blue">immunotherapy</font>;           •   <font color="blue">announcement</font>s <font color="blue">concerning</font> Xcyte’s <font color="blue">competitors</font> or the <font color="blue">biotechnology</font>     industry in general;           •   <font color="blue">new regulatory pronouncements</font> and changes in <font color="blue">regulatory guidelines</font>;           •   general and industry-specific economic <font color="blue">conditions</font>;           •   changes in financial estimates or <font color="blue">recommendations by securities</font>     analysts;           •   <font color="blue">variations</font> in Xcyte’s quarterly results;           •   <font color="blue">announcement</font>s about Xcyte’s <font color="blue">collaborators</font> or <font color="blue">licensors</font>; and           •   changes in <font color="blue">accounting</font> principles</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font>s of the securities of <font color="blue">biotechnology</font> companies, particularly     <font color="blue">companies without product revenues</font> and earnings, have <font color="blue">been <font color="blue">highly volatile</font></font>     and are likely to <font color="blue">remain <font color="blue">highly volatile</font></font> in the future</td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font> has     often been unrelated to the performance of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>In the     past, companies that experience <font color="blue">volatility</font> in the <font color="blue">market price</font> of their     securities have <font color="blue">often faced securities</font> class <font color="blue">action <font color="blue">litigation</font></font></td>
    </tr>
    <tr>
      <td>Moreover,     <font color="blue">market price</font>s for stocks of <font color="blue">biotechnology</font>-related and <font color="blue">technology companies</font>     <font color="blue">frequently reach levels</font> that <font color="blue">bear no relationship</font> to the performance of     these companies</td>
    </tr>
    <tr>
      <td>These <font color="blue">market price</font>s generally are not sustainable and are     <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>Whether or not <font color="blue">meritorious</font>, <font color="blue">litigation</font> brought against     Xcyte  could  result in substantial costs, divert Xcyte’s <font color="blue">management</font>’s     attention and resources and harm Xcyte’s <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Xcyte’s <font color="blue">certificate</font> of in<font color="blue">corporation</font> and bylaws and <font color="blue">certain provisions</font> of     <font color="blue">Delaware </font><font color="blue">law may delay</font> or prevent a change in Xcyte’s <font color="blue">management</font> and make it     more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire Xcyte</td>
    </tr>
    <tr>
      <td>Xcyte’s <font color="blue">certificate</font> of in<font color="blue">corporation</font> and <font color="blue">bylaws contain provisions</font> that     <font color="blue">could delay</font> or prevent a change in its board of <font color="blue">directors</font> and <font color="blue">management</font>     teams</td>
    </tr>
    <tr>
      <td>Some of these provisions:           •   authorize the issuance of <font color="blue">preferred stock</font> that can be created and     issued by the board of <font color="blue">directors</font> without prior stockholder approval,     commonly referred to as “blank check” <font color="blue">preferred stock</font>, with rights senior to     those of Xcyte <font color="blue">common stock</font>;           •   provide for the board of <font color="blue">directors</font> to be <font color="blue">divided into three classes</font>;     and           •   require that <font color="blue">stockholder actions must</font> be <font color="blue">effected at</font> a duly called     <font color="blue">stockholder meeting</font> and <font color="blue">prohibit stockholder action by written consent</font></td>
    </tr>
    <tr>
      <td>In addition, because Xcyte is <font color="blue">incorporated</font> in Delaware, Xcyte is <font color="blue">governed by</font>     the provisions of Section 203 of the <font color="blue">Delaware </font>General Corporation Law, which     limits the ability of large <font color="blue">stockholders</font> to complete a business <font color="blue">combination</font>     with, or <font color="blue">acquisition</font> of Xcyte</td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions may prevent</font> a business     <font color="blue">combination</font> or <font color="blue">acquisition</font> that would be attractive to <font color="blue">stockholders</font> and     <font color="blue">could limit</font> the price that <font color="blue">investors would</font> be willing to pay in the future     for Xcyte’s stock</td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions also</font> make it more <font color="blue">difficult</font> for Xcyte’s <font color="blue">stockholders</font> to     replace  members  of  its board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Because Xcyte’s board of     <font color="blue">directors</font> is responsible for appointing the members of its <font color="blue">management</font> team,     these <font color="blue">provisions could</font> in turn affect any attempt to replace Xcyte’s current     <font color="blue">management</font> team</td>
    </tr>
    <tr>
      <td>Additionally, these <font color="blue">provisions may prevent</font> an <font color="blue">acquisition</font>     that would be attractive to <font color="blue">stockholders</font> and <font color="blue">could limit</font> the price that     <font color="blue">investors would</font> be willing to pay in the future for Xcyte <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The future sale of Xcyte’s common and convertible <font color="blue">preferred stock</font>, and     <font color="blue">future issuances</font> of Xcyte <font color="blue">common stock</font> upon <font color="blue">conversion</font> of its convertible     <font color="blue">preferred stock</font> and upon the payment of make-whole dividends, if any, could     <font color="blue">negatively affect</font> Xcyte’s stock price</td>
    </tr>
    <tr>
      <td>If Xcyte’s common or <font color="blue">convertible preferred</font> <font color="blue">stockholders</font> sell substantial     amounts of its stock in the <font color="blue">public market</font>, or the market perceives that such     sales  may  occur,  the <font color="blue">market price</font> of Xcyte’s common and convertible     <font color="blue">preferred stock</font> could fall</td>
    </tr>
    <tr>
      <td>In addition, if Xcyte exercises its rights to pay make-whole dividends in     common  stock  rather  than in <font color="blue">cash upon <font color="blue">conversion</font></font> of its convertible     <font color="blue">preferred stock</font> to <font color="blue">common stock</font>, then the sale of such shares of common     stock or the <font color="blue">perception</font> that <font color="blue">such sales may</font> occur could cause the market     price of Xcyte’s stock to fall</td>
    </tr>
    <tr>
      <td>Additionally, after Xcyte’s convertible     <font color="blue">preferred stock</font> offering, the holders of its convertible <font color="blue">preferred stock</font> had     the right to <font color="blue">convert each</font> share of convertible                                           10     ______________________________________________________________________    [36]Table of <font color="blue">Contents       </font><font color="blue">preferred stock</font> into <font color="blue">approximately</font> 4dtta2553 shares of its <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue"><font color="blue">conversion</font> rate</font> is subject to certain antidilution adjustments that, upon     the occurrence of certain events, will increase the number of shares of     <font color="blue">common stock</font> that <font color="blue">each holder</font> of convertible <font color="blue">preferred stock</font> will receive     upon <font color="blue">conversion</font> into <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Such antidilution price adjustments may     apply in the case of any <font color="blue">strategic alternative</font> that Xcyte <font color="blue">pursues which may</font>     result in <font color="blue">further dilution</font> to the holders of outstanding <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">conversion</font> of Xcyte convertible <font color="blue">preferred stock</font> into <font color="blue">common stock</font> and the     payment of any make-whole dividends in shares of <font color="blue">common stock</font> in lieu of     cash, may result in substantial dilution to the interests of Xcyte’s holders     of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">After Xcyte </font>convertible <font color="blue">preferred stock</font> offering, according to the terms of     Xcyte’s <font color="blue">investors rights agreement</font>, the holders of <font color="blue">approximately</font> 9dtta0 million     shares  of Xcyte <font color="blue">common stock</font> and warrants had rights, subject to some     <font color="blue">conditions</font>, to require Xcyte to file <font color="blue">registration</font> statements covering their     shares  of  <font color="blue">common stock</font> or to include their shares of <font color="blue">common stock</font> in     <font color="blue">registration</font>  statements  that  Xcyte  may  file  for  itself or other     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Furthermore, if Xcyte were to include in a company-initiated     <font color="blue">registration</font> statement shares of <font color="blue">common stock</font> held by those <font color="blue">holders pursuant</font>     to the exercise of their <font color="blue">registration</font> rights, those <font color="blue">sales could impair</font> its     ability to raise needed <font color="blue">capital by depressing</font> the <font color="blue">price at which</font> it could     sell its <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If Xcyte exchanges the convertible <font color="blue">preferred stock</font> for <font color="blue"><font color="blue">debenture</font>s</font>, the     <font color="blue">exchange will</font> be taxable but Xcyte will not provide any cash to pay any tax     <font color="blue">liability</font> that any convertible <font color="blue">preferred stock</font>holder may incur</td>
    </tr>
    <tr>
      <td>An exchange of convertible <font color="blue">preferred stock</font> for <font color="blue"><font color="blue">debenture</font>s</font>, as well as any     dividend make-whole or interest make-whole payments paid in Xcyte common     stock, will be <font color="blue">taxable events</font> for US federal income tax purposes, which     may result in tax <font color="blue">liability</font> for the holder of convertible <font color="blue">preferred stock</font>     without any <font color="blue">corresponding receipt</font> of cash by the holder</td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue"><font color="blue">debenture</font>s</font> may be <font color="blue">treated as</font> having original issue discount, a portion of     <font color="blue">which would generally</font> be required to be included in the holder’s gross     income <font color="blue">even though</font> the cash to <font color="blue">which such income</font> is <font color="blue">attributable would</font> not     be received <font color="blue">until maturity</font> or <font color="blue">redemption</font> of the <font color="blue">debenture</font></td>
    </tr>
    <tr>
      <td>Xcyte will not     distribute any cash to you to pay these potential tax <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>If Xcyte <font color="blue"><font color="blue">automatically</font> convert</font>s the convertible <font color="blue">preferred stock</font>, there is a     substantial risk of <font color="blue">fluctuation</font> in the price of Xcyte <font color="blue">common stock</font> from the     date it elects to <font color="blue"><font color="blue">automatically</font> convert</font> to the <font color="blue">conversion</font> date</td>
    </tr>
    <tr>
      <td>Xcyte may elect to <font color="blue"><font color="blue">automatically</font> convert</font> the convertible <font color="blue">preferred stock</font> on     or prior to maturity if Xcyte <font color="blue"><font color="blue">common stock</font> price</font> has exceeded 150prca of the     <font color="blue">conversion</font> price for at least 20 trading days during a 30-day trading period     ending <font color="blue">within five trading days prior</font> to the notice of automatic <font color="blue">conversion</font></td>
    </tr>
    <tr>
      <td>You should be aware that there is a risk of <font color="blue">fluctuation</font> in the price of     Xcyte <font color="blue">common stock</font> between the time when it <font color="blue">may first elect</font> to <font color="blue">automatically</font>     convert the preferred and the automatic <font color="blue">conversion</font> date</td>
    </tr>
    <tr>
      <td>Xcyte does not intend to <font color="blue">pay cash dividends on</font> its <font color="blue">common stock</font> in the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Xcyte does not anticipate <font color="blue">paying cash dividends on</font> its <font color="blue">common stock</font> in the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Any payment of <font color="blue">cash dividends will depend on</font> Xcyte’s     financial  condition, results of <font color="blue">operations</font>, capital <font color="blue"><font color="blue">requirement</font>s</font>, the     outcome of the review of Xcyte’s <font color="blue"><font color="blue">strategic alternative</font>s</font> and other factors     and will be at the <font color="blue">discretion</font> of Xcyte’s board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Accordingly,     <font color="blue">investors will</font> have to <font color="blue">rely on capital appreciation</font>, if any, to earn a     return on their <font color="blue">investment</font> in Xcyte <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Furthermore, Xcyte may in     the <font color="blue">future become</font> subject to <font color="blue">contractual restrictions on</font>, or <font color="blue">prohibitions</font>     against, the payment of dividends</td>
    </tr>
  </tbody>
</table>